Jeffrey Goodman, MD
Nephrology · Florham Park, NJNPI 1316977416
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $55,263 of the $69,602 with a category attached, or 79.4%. 29 manufacturers reported payments, led by AstraZeneca at 48.1% of the total. Reporting peaked in 2023 at $25,726 and has fallen 76.5% since, to $6,051 in 2025. Among nephrology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 453 payments — averaging $153.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$34K
- Bayer$27K
- Fresenius USA Marketing, Inc.$5K
- Vifor Pharma, Inc.$625
- Amgen$596
- Ardelyx, Inc.$382
- plus $3K from 23 others
What the payments were for
- Speaking & faculty fees$55,26379%
- Travel & lodging$4,3196%
- Food & beverage$9,80714%
- Education$2130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 128 | $33,501 |
| Bayer | 56 | $27,088 |
| Fresenius USA Marketing, Inc. | 11 | $4,616 |
| Vifor Pharma, Inc. | 40 | $625 |
| Amgen(2 entities) | 32 | $596 |
| Ardelyx, Inc. | 25 | $382 |
| Travere Therapeutics, Inc. | 20 | $377 |
| GSK | 17 | $343 |
| Otsuka America Pharmaceutical, Inc. | 20 | $339 |
| OPKO Pharmaceuticals, LLC | 20 | $273 |
| Akebia Therapeutics Inc | 15 | $241 |
| Calliditas Therapeutics US Inc. | 13 | $222 |
| Novartis | 13 | $221 |
| AbbVie | 1 | $122 |
| Azurity Pharmaceuticals, Inc. | 6 | $97 |
| Aurinia Pharma U.S., Inc. | 6 | $80 |
| Novo Nordisk | 4 | $71 |
| Lilly USA, LLC | 4 | $66 |
| Mallinckrodt Hospital Products Inc. | 4 | $62 |
| Apellis Pharmaceuticals, Inc. | 3 | $51 |
| Scpharmaceuticals Inc. | 3 | $46 |
| Boehringer Ingelheim | 3 | $46 |
| AMAG Pharmaceuticals, Inc. | 3 | $43 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
| Renalytix AI, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Strongbridge US Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$69,602 in reported general payments places this provider in the 95th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 375 | $276,514 |
| VeltassaPatiromer Calcium Sorbitex | 131 | $138,881 |
| KerendiaFinerenone | 94 | $97,709 |
| VelphoroSucroferric Oxyhydroxide | 29 | $77,475 |
| JardianceEmpagliflozin | 66 | $52,856 |
| EntrestoSacubitril/Valsartan | 40 | $46,322 |
| LokelmaSodium Zirconium Cyclosilicate | 50 | $44,684 |
| Sevelamer Carbonate | 153 | $25,403 |
| Cinacalcet Hcl | 66 | $14,679 |
| SpsSodium Polystyrene Sulfon/Sorb | 25 | $10,648 |
| Torsemide | 462 | $9,312 |
| Potassium Citrate ErPotassium Citrate | 78 | $8,338 |
| Calcitriol | 358 | $8,298 |
| Chlorthalidone | 376 | $6,615 |
| Valsartan | 208 | $5,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $33,501 | $321,198425 claims |
| BayerKerendia | $27,088 | $97,70994 claims |
| Fresenius USA Marketing, Inc.Velphoro | $4,616 | $77,47529 claims |
| Boehringer IngelheimJardiance | $46 | $52,85666 claims |
| NovartisEntresto | $221 | $46,32240 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $19 | $5,191208 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Florham Park
- Robert ZenenbergFlorham Park$13K
- Kezia AlbertoFlorham Park$7K
- Seema KaranjgaokarFlorham Park$6K
- Lawrence ByrdLivingston$338K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
- Harry DounisNeptune$75K
- Kenneth LissEatontown$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.